The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Key topics on AML at EHA 2017
Oliver Ottmann
• 25 Aug 2017
Oliver Ottmann, MD, FRCPath from Cardiff University, Cardiff, UK gives us an overview of four major topics covered at the 2017 European Hematology Association (EHA) annual congress in Madrid, Spain regarding acute myeloid leukemia (AML). Prof. Ottmann talks to us about the impact that these topics, including minimal residual disease analysis, will have in the field of AML research and treatment.
